Objective-Restenosis after angioplasty remains a major clinical problem. Prostaglandin E 2 (PGE 2 ) plays an important role in vascular homeostasis. The PGE 2 receptor E-prostanoid 2 (EP2) is involved in the proliferation and migration of various cell types. We aimed to determine the role of EP2 in the pathogenesis of neointimal formation after vascular injury. Methods and Results-Wire-mediated vascular injury was induced in the femoral arteries of male wild-type (EP2ϩ/ϩ) and EP2 gene-deficient (EP2Ϫ/Ϫ) mice. In EP2ϩ/ϩ mice, EP2 mRNA expression was increased in injured vessels for at least 4 weeks after vascular injury. Neointimal hyperplasia was markedly accelerated in EP2Ϫ/Ϫ mice, which was associated with increased proliferation and migration of vascular smooth muscle cells (VSMCs) and increased cyclin D1 expression in the neointima layer. Platelet-derived growth factor-BB (PDGF-BB) treatment resulted in more significant cell proliferation and migration in VSMCs of EP2Ϫ/Ϫ mice than in those of EP2ϩ/ϩ mice. Activation and overexpression of EP2 attenuated PDGF-BB-elicited cell proliferation and migration, induced G 1 3 S-phase arrest and reduced PDGF-BB-stimulated extracellular signal-regulated kinase phosphorylation in EP2ϩ/ϩ VSMCs. Conclusion-These findings reveal a novel role of the EP2 receptor in neointimal hyperplasia after arterial injury. The EP2 receptor may represent a potential therapeutic target for restenosis after angioplasty. (Arterioscler Thromb Vasc Biol.
P ercutaneous transluminal coronary angioplasty (PTCA) has been widely used for treating coronary atherosclerosis. However, many patients undergoing PTCA experience postangioplasty restenosis. 1 Although new devices for dilatation of stenosed arteries have lowered the incidence of acute complications, restenosis remains a major obstacle in the long-term outcome of PTCA interventions. 2 Restenosis is defined as the healing response of the arterial wall to mechanical injury and consists of 2 main processes: neointimal hyperplasia (smooth muscle migration/proliferation and extracellular matrix deposition) and vessel remodeling. 3 Platelet-derived growth factor-BB (PDGF-BB), an important growth factor released from platelets and leukocytes, plays a critical role in intimal hyperplasia after vascular injury. 4, 5 An enormous amount of research has elucidated the molecular pathways involved in neointimal formation and vascular remodeling after vascular injury and has greatly advanced our understanding of the mechanisms contributing to the pathogenesis of restenosis. 6 -8 These efforts have led to many new strategies for effective prevention and treatment options for restenosis.
Prostaglandin E 2 (PGE 2 ), a major arachidonic acid metabolite, is produced in the vasculature via a mechanism dependent on cyclooxygenase (COX) and prostaglandin E synthase. PGE 2 has important roles in the regulation of blood pressure, inflammatory response, immune response, and energy metabolism. 9 -11 Moreover, an increasing amount of evidence suggests that PGE 2 is critical in maintaining vascular homeostasis and participates in the pathogenesis of many vascular diseases, including atherosclerosis and restenosis. 12,13 PGE 2 production is increased in atherosclerotic lesions of both laboratory animals and humans. 14, 15 COX-1 and microsomal PGE 2 synthase-1 (mPGES-1) are expressed in normal vessels, 16 whereas COX-2 and mPGES-1 expression is induced in wire-injured 17 and balloon-injured 18 vessels. These observations suggest that PGE 2 may have an important role in vascular remodeling after angioplasty. PGE 2 exerts its physiological roles via 4 functionally related E-prostanoid (EP) receptors, designated EP1, EP2, EP3, and EP4. 19, 20 The EP2 receptor is coupled to Gs protein, and the intracellular cAMP level is increased on its activation. 21 The EP2 receptor can facilitate ovulation and fertilization 22 and inhibit the proliferation of many types of cells, including NFS-60 cells, 23 rat hepatic stellate cells, 24 and asthmatic ASM cells. 25 Importantly, the EP2 receptor is the most predominant PGE 2 receptor in vascular smooth muscle cells (VSMCs). 26 In the present study, we found that the expression of the EP2 receptor was increased in injured arteries, where its activation may attenuate neointimal formation by inhibiting VSMC proliferation and migration after angioplasty.
Methods

Reagents
The PGE 2 EIA Kit and butaprost were from Cayman Chemical (Ann Arbor, MI). Antibodies against COX-2, mPGES-1, EP1, EP2, EP3, and EP4 were also from Cayman Chemical. Antibodies against extracellular signal-regulated kinase 1/2 (ERK1/2), phosphor-ERK1/2, and cyclin D1 were from Cell Signaling Technology (Danvers, MA). PDGF-BB and 5-bromo-2Ј-deoxyuridine (BrdU) were from Sigma-Aldrich (St. Louis, MO). An adenovirus expressing a hemagglutinin-tagged full-length human EP2 cDNA (Ad-EP2) (a gift from Dr. R. Breyer, Vanderbilt University) and a full-length green fluorescent protein (GFP) cDNA (Ad-GFP) were constructed by SinoGenoMax (Beijing, China). Other reagents were from SigmaAldrich unless specified.
Experimental Animals and Femoral Artery Injury
We used male mice, 12 to 16 weeks old, in a C57BL/6 background. The use of the animals was approved by the Animal Experimentation Committee of Peking University Health Science Center. The EP2 receptor-deficient (EP2Ϫ/Ϫ) mice were generated as previously described, 9 and the lack of functional EP2 receptor was confirmed by reverse transcription-polymerase chain reaction (reverse transcription-PCR) and Western blot analysis (Supplemental Figure I , available online at http://atvb.ahajournals.org). Wire-mediated vascular injury was induced in the right femoral arteries of EP2Ϫ/Ϫ mice and age-and gender-matched wild-type (EP2ϩ/ϩ) mice by endoluminal passage of an angioplasty guide wire as previously described. 27 The uninjured left femoral arteries served as negative controls. In brief, mice were anesthetized with intraperitoneal injection of 10% chloral hydrate (4 mL/kg body weight). Right femoral arteries were exposed by a longitudinal groin incision and monitored under a surgical microscope. After the distal portion of the artery was encircled with an 8-0 nylon suture, a vascular clamp was placed proximally at the level of the inguinal ligament, and a guide wire 0.38 mm in diameter (Micro Therapeutics, Irvine, CA) was introduced into the arterial lumen through an arteriotomy made in the distal perforating branch. After release of the clamp, the guide wire was advanced to the level of the aortic bifurcation and was left in place for 1 minute to denude and dilate the artery. Then, the wire was removed, and the silk suture was looped at the proximal portion of the muscular branch artery was secured. Blood flow in the femoral artery was restored by releasing the sutures placed in the proximal and distal femoral portions. The skin incision was closed with a 5-0 silk suture. Animals were monitored as routine after surgery.
RNA Extraction and Real-Time PCR
Femoral artery segments were quickly dissected and snap-frozen in liquid nitrogen. 28 Vascular tissues were pooled from at least 4 animals, and total RNA was extracted by use of Trizol reagent (Life Technologies). Total RNA was reverse transcribed to cDNA by use of the TaqMan Reverse Transcription Reagents kit (Applied Biosystems) according to the manufacturer's protocol. Real-time PCR was performed with use of iCycler with the SYBR Green I probe (Bio-Rad, Hercules, CA). Each sample was analyzed in triplicate and normalized to the level of GAPDH mRNA. The PCR protocol was 95°C for 30 s, 59°C to 60°C for 30 s, and 72°C for 30 s, for 40 cycles, followed by a final extension at 72°C for 7 minutes. The primer sequences are in Supplemental Table I . PCR products were validated by electrophoresis on 2% agarose.
Cell Culture
Primary mouse VSMCs were cultured as described previously. 29 In brief, 12-to 16-week old male C57BL/6 mice were anesthetized by intraperitoneal injection of 10% chloral hydrate (4 mL/kg body weight), and whole aortas were quickly dissected. After removal of adventitial connective tissues and luminal endothelial cells, the aortas were chopped into pieces of approximately 1 mm 2 and digested in 10 mL of Dulbecco's modified Eagle's medium (Gibco, Invitrogen) containing 1 mg/mL collagenase II and 20 U/mL elastase (Sigma-Aldrich) for 40 minutes at 37°C. The digested samples were then centrifuged at 1500 rpm for 10 minutes, and the precipitate was resuspended in 4 mL of growth medium (Dulbecco's modified Eagle's medium supplemented with 20% fetal bovine serum [Hyclone]). Cell suspension was then transferred to a fibronectin (Becton Dickinson, Franklin Lakes, NJ)-coated 35-mm 2 cell culture flask. The cells were cultured at 37°C in a humidified incubator containing 5% CO 2 . Cells at passages 3 to 7 were used. Each individual experiment was repeated at least 3 times with different cell preparations.
Tissue Preparation, Histology, and Morphometry
Mice were euthanized on the days 4, 7 and 28 after arterial injury. Animals were perfused with PBS for 5 minutes and then 4% paraformaldehyde for 20 minutes via cannulation of the left ventricle. The hindlimbs were then harvested en bloc, fixed in 4% paraformaldehyde overnight, and decalcified in formic acid bone decalcifier (Zhongshan Golden Bridge, Beijing, China) for 3 hours. Tissues containing the femoral artery were embedded in paraffin wax and cut into 5-m sections for further analysis.
Six to 10 sections per femoral artery at 100-m intervals were examined by hematoxylin and eosin staining, and sections from the area with maximal injury response were further evaluated by staining with combined Masson's elastin stain to visualize the arterial wall layers or for immunohistochemistry. The intima and media areas were measured by computerized morphometry with Image-Pro Plus 6.1 (Media Cybernetics, Bethesda, MD). Intimal hyperplasia was defined as the formation of a neointimal layer within the internal elastic lamina (IEL). Medium area was calculated as the area encircled by the external elastic lamina minus the area encircled by IEL. The intima-to-media ratio was calculated as the intimal area divided by the medial area. Arteries with a broken IEL or thrombosis as demonstrated by combined Masson's elastin stain were excluded from the study.
Immunohistochemistry
For immunohistochemistry, the artery sections were incubated with primary antibodies against ␣-smooth muscle actin (Sigma-Aldrich), F4/80 (Abcam, Cambridge, MA), and cyclin D1 (Cell Signaling Technology, Danvers, MA), followed by incubation with horseradish peroxidase-conjugated secondary antibody (Zhongshan Golden Bridge, Beijing, China). After several washings with PBS, samples underwent successive diaminobenzidine (DAB) staining, hematoxylin restaining, dehydration, and cover glass mounting.
To detect the vascular cell replication rate in vivo, mice were intraperitoneally injected with BrdU (30 mg/kg) at 8-hour intervals 3 times before mice were killed. 6 Cryosections of arterial segments were denatured with 1.5 N HCl, reacted with anti-BrdU antibody (Zhongshan Golden Bridge, Beijing), and detected with horseradish peroxidase-conjugated antibody.
Cell Proliferation and Cell Cycle
Cell proliferation was evaluated by direct cell counting as described previously. 7 For cell cycle analysis, VSMCs synchronized by serum starvation for 48 hours were treated with PDGF-BB (Sigma-Aldrich) for 16 hours. Cells were harvested, fixed, and stained with use of Cycle Test Plus DNA Reagent Kit (Becton Dickinson) and analyzed for DNA content by flow cytometry by FACScan (Becton Dickinson).
Scratch-Induced Wound Healing Assay and Transwell Migration Assay
VSMCs were plated in fibronectin-coated 6-well plates. Cells were grown to subconfluence (80%) overnight in Dulbecco's modified Eagle's medium supplemented with 20% fetal bovine serum. Cells were serum starved for 48 hours. Confluent monolayers were scratched with use of P200 Gilson pipette tips as described. 30 Images under phase-contrast microscopy were taken at 0, 6, and 12 hours after the scratching. The width between the wound edges in each well at each time was measured at fixed points by use of a standard template placed on the image. Data were expressed as closure rate (percentage) based on initial wound width.
Analysis of VSMC invasion involved use of Transwell plates 6.5 mm in diameter with polycarbonate membrane filters containing 8-m pores (Corning, Corning, NY). 31 The lower chamber contained PDGF-BB (10 g/L) as a chemoattractant. After 12 hours, the cells on the upper surface were removed by gentle abrasion with a cotton bud, and the cells on the underside (invaded cells) were fixed with methanol and stained by the hematoxylin and eosin technique. Migrated cells were quantified by the average of 4 randomly chosen high-power fields of 3 independent duplicate experiments.
Statistical Analysis
All values are expressed as meanϮSEM. Data were analyzed by Student t test (paired groups) or 2-way ANOVA, followed by Bonferroni's post test correction (multigroup comparisons). PϽ0.05 was considered statistically significant.
Results
EP2 Expression in Injured Arteries and in PDGF-BB-Treated VSMCs
We analyzed the mRNA expression of the 4 EP receptors (EP1, EP2, EP3, and EP4) and 2 inducible prostaglandin E (PGE)-synthesizing enzymes (COX-2 and mPGES-1) by real-time PCR in femoral arteries of mice at 4, 7, and 28 days after wire injury. At 4 days after injury, the mRNA levels of COX-2, mPGES-1, and EP2 were significantly increased, with no change in the levels of EP1, EP3, and EP4 ( Figure  1A ). At days 7 and 28, the levels of mPGES-1 and EP2 remained high, whereas that of EP3 was decreased, with no change in COX-2, EP1, and EP4 expression. These findings suggest that injured vasculatures exhibited enhanced PGE 2 biosynthesis and sustained EP2 signaling. In addition, the mRNA levels of EP1, EP3, and EP4 in injured femoral arteries of EP2Ϫ/Ϫ mice were also analyzed. As shown in Supplemental Figure II , EP1 expression was significantly decreased at day 28 after vascular injury, whereas EP3 expression was markedly increased at day 4, returned to the basal level at day 7, and was significantly reduced at day 28 following wire damage. In contrast, EP4 expression remained unchanged at day 4 but was significantly downregulated at days 7 and 28 (Supplemental Figure II) .
Next, we evaluated the effect of PDGF-BB on the expression of COX-2, mPGES-1, and the EP1, EP2, EP3, and EP4 receptors in cultured EP2ϩ/ϩ mouse VSMCs. Treatment with PDGF-BB for 24 hours significantly upregulated the protein expression of COX-2, mPGES-1, and EP2 receptors but had little effect on the protein levels of EP1, EP3, and EP4 receptors ( Figure 1B ). Furthermore, EP2 expression was increased 8 hours after PDGF-BB treatment and remained high for at least 72 hours ( Figure 1C ). These results suggest that the EP2 receptor may play an important role in PDGFinduced VSMC proliferation and migration.
Effect of EP2 Gene Deficiency on Neointima Formation After Vascular Injury
To further determine the role of the EP2 receptor in intimal hyperplasia in vivo, we evaluated neointimal formation in EP2Ϫ/Ϫ mice 28 days after wire injury. Compared with EP2ϩ/ϩ mice, EP2Ϫ/Ϫ mice showed markedly augmented neointimal formation (Figure 2A ). Quantitative morphometry further confirmed a significant increase in the intima-tomedia ratio (2.95Ϯ0.19 versus 1.43Ϯ0.08) and neointimal area (28 860Ϯ4475 versus 9109Ϯ872 m 2 ) in EP2Ϫ/Ϫ than EP2ϩ/ϩ arteries ( Figure 2B and 2C) . Consistently, the luminal area was significantly reduced in EP2Ϫ/Ϫ than EP2ϩ/ϩ arteries (13 150Ϯ3272 versus 29 710Ϯ4356 m 2 ) ( Figure 2D ). To characterize the cell composition of the neointima, EP2Ϫ/Ϫ and EP2ϩ/ϩ arteries were stained with molecular markers for VSMCs (␣-smooth muscle actin) and macrophages (F4/80). Immunohistochemical staining revealed that cells present in the neointima at day 28 after injury were predominantly ␣-smooth muscle actin-positive VSMCs, with few macrophages in EP2Ϫ/Ϫ or EP2ϩ/ϩ arteries ( Figure 2E ). Consistent with the augmented neointimal hyerplasia, the cell number in the neointimal layer was significantly higher in EP2Ϫ/Ϫ than EP2ϩ/ϩ arteries after vascular injury (Supplemental Figure III) .
The Role of EP2 in VSMC Proliferation In Vivo and In Vitro
BrdU incorporation assay revealed significantly higher neointimal BrdU-positive cell numbers in EP2Ϫ/Ϫ than EP2ϩ/ϩ mice ( Figure 3A ) at day 7 after vascular injury. To further confirm whether the EP2 receptor is involved in regulating the proliferation of VSMCs, we evaluated the effect of selective activation of the EP2 receptor or overexpression of the EP2 receptor on proliferation of cultured VSMCs. A recombinant adenovirus expressing the human EP2 receptor with a hemagglutinin tag (Ad-EP2) was constructed and characterized by immunoprecipitation assay (Supplemental Figure IV) . In cultured EP2ϩ/ϩ VSMCs, treatment with butaprost, a selective EP2 receptor agonist, at 10, 100 and 500 nmol/L for 24 hours dose-dependently inhibited VSMC proliferation (Supplemental Figure V) . Butaprost (100 nmol/L) also suppressed PDGF-BB-induced VSMC proliferation time-dependently within 72 hours. In contrast to EP2ϩ/ϩ VSMCs, EP2Ϫ/Ϫ VSMCs showed enhanced cell proliferation in response to PDGF-BB treatment, which could not be inhibited by butaprost ( Figure 3B ). In addition, adenovirus-mediated overexpression of the EP2 receptor significantly inhibited PDGF-BB-induced proliferation of EP2ϩ/ϩ VSMCs, which was blocked by indomethacin-mediated inhibition of endogenous PGE 2 synthesis (Figure 3C) . In EP2Ϫ/Ϫ VSMCs, overexpression of the EP2 receptor restored the inhibitory effect of butaprost on PDGF-BB-induced VSMC proliferation ( Figure 3D ).
To further characterize the underlying molecular mechanism by which the EP2 receptor inhibits VSMC proliferation, we evaluated the effect of butaprost or EP2 overexpression on cell cycle progression in PDGF-BB-treated EP2ϩ/ϩ VSMCs. After PDGF-BB treatment (10 ng/mL) for 16 hours, a significant number of VSMCs moved from the G 0 /G 1 phase to the S phase, which was significantly attenuated by butaprost pretreatment (Supplemental Figure VI) . Similarly, Ad-EP2 overexpresssion induced G 0 /G 1 arrest in VSMCs, which was almost completely reversed by indomethacin (Supplemental Figure VI) . These findings suggest that the PGE 2 -EP2 signaling pathway may suppress PDGF-BB-induced VSMC proliferation.
Effect of EP2 on Cyclin D1 Expression in the Neointima and PDGF-Treated VSMCs
Consistent with the findings of BrdU incorporation ( Figure  3A) , the number of neointimal cyclin D-positive cells was significantly greater in EP2Ϫ/Ϫ than in EP2ϩ/ϩ mice ( Figure 4A and 4B) , which suggests that EP2 may inhibit cyclin D1 expression. In support of this hypothesis, both butaprost treatment ( Figure 4C ) and Ad-EP2 infection (Figure 4D ) significantly attenuated PDGF-induced cyclin D1 expression in EP2ϩ/ϩ VSMCs. In addition, the attenuation of PDGF-induced cyclin D1 expression by EP2 overexpression was almost completely blocked by the inhibition of endogenous prostaglandin biosynthesis with indomethacin ( Figure 4D) . Moreover, the expression of cyclin D1 was higher in EP2Ϫ/Ϫ than EP2ϩ/ϩ VSMCs after treatment with PDGF ( Figure 4E ). Collectively, these findings further support that the PGE 2 -EP2 signaling axis may ameliorate PDGF-stimulated VSMC proliferation by inducing G 0 /G 1 cell cycle arrest.
Role of EP2 in VSMC Migration In Vivo and In Vitro
To determine whether EP2 is involved in regulating the migration of VSMCs, we evaluated neointimal formation soon after wire injury. 32 First, we measured the number of VSMCs in the intima 4 days after injury, when cells first migrate in but do not replicate, to examine VSMC migration from the media to the intima. 33 The number of neointimal cells was significantly higher in EP2Ϫ/Ϫ than EP2ϩ/ϩ mice ( Figure 5A and 5B), which suggests EP2 may limit VSMC migration. To further confirm this speculation, we evaluated the effect of selective activation of EP2 receptor or overexpression of the EP2 receptor on migration of EP2ϩ/ϩ VSMCs. Using the scratch assay, we found that both butaprost treatment and overexpression of EP2 inhibited PDGF-induced migration of EP2ϩ/ϩ VSMCs, and the effect of EP2 overexpression was almost completely ameliorated by indomethacin treatment (Figure 5C and 5D ). An invasion assay with PDGF-BB used as a chemoattractant conferred similar results ( Figure 5E and 5F, Supplemental Figure VIIA and VIIB). In addition, the migration ability of EP2Ϫ/Ϫ VSMCs was stronger than EP2ϩ/ϩ VSMCs in response to PDGF ( Figure 5G, Supplemental Figure VIIC) . Therefore, PGE 2 signaling via the EP2 receptor inhibits the migration of VSMCs in vivo and in vitro.
Effect of EP2 on PDGF-Induced ERK Phosphorylation in Cultured VSMCs
Because long-term activation of ERK is essential for cell cycle progression and migration 34 -37 and the cAMP/protein kinase A (PKA) signaling pathway can arrest cells in the G 1 phase by suppressing the phosphorylation of ERK, 38 we determined the effect of butaprost and Ad-EP2 infection on PDGF-mediated ERK activation. As a selective EP2 receptor agonist, butaprost significantly elevated intracellular cAMP levels in EP2ϩ/ϩ VSMCs (Supplemental Figure VIII) . Both 
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butaprost pretreatment and overexpression of EP2 markedly suppressed PDGF-stimulated phosphorylation of ERK in EP2ϩ/ϩ VSMCs ( Figure 6A and 6B). The inhibitory effect of Ad-EP2 on PDGF-induced ERK activation seemed to depend on endogenous PGE 2 production, because indomethacin treatment completely blocked this effect in EP2ϩ/ϩ VSMCs ( Figure 6C , Supplemental Figure IX ). In addition, deletion of EP2 significantly enhanced PDGF-induced ERK activation ( Figure 6D ). Thus, the PGE 2 -EP2 signaling axis may inhibit VSMC proliferation and migration by suppressing ERK activation in response to PDGF.
Discussion
Restenosis after angioplasty remains a major clinical problem that has not been solved since PTCA was introduced into clinical practice. Proliferation and migration of VSMCs in the arterial wall plays pivotal roles in atherosclerosis and restenosis. 39, 40 In the present study, we demonstrated an increased expression of the PGE 2 EP2 receptor in wire-injured arteries and in PDGF-treated VSMCs. We also showed that neointimal formation was significantly augmented in EP2-deficient mice. Finally, both selective activation and overexpression of the EP2 receptor markedly suppressed PDGF-induced VSMC proliferation and migration, which was associated with G 0 /G 1 cell cycle arrest, decreased expression of cyclin D1, and attenuation of phosphorylation of ERK1/2. Collectively, these findings suggest that the PGE 2 -EP2 signaling pathway may play an important role in regulating neointimal formation in response to vascular injury. Activation of the EP2 receptor may ameliorate restenosis by inhibiting VSMC proliferation and migration. A key finding of the present study is that PGE 2 may have a beneficial effect on neointimal hyperplasia via activation of the EP2 receptor. PGE 2 is implicated in the inflammatory response and in upregulation of matrix metalloproteinases in human atherosclerotic plaques, thus contributing to plaque instability. 41 Inhibition of COX-2 activity 42 and deletion of a terminal PGE 2 synthase, mPGES-1, 43 retard atherogenesis in mice. In addition, several lines of evidence suggest a beneficial effect of COX-2 and mPGES-1 inactivation on neointimal hyperplasia. 17, 44, 45 These findings indicate that COX-2/ mPGES-1-derived PGE 2 may augment atherosclerosis and restenosis. However, this conclusion is not supported by several recent reports showing that inhibition of COX-2-derived PGE 2 exacerbated atherosclerosis, 12,46 so whether PGE 2 is beneficial in reducing atherosclerosis development remains controversial. In addition, although the effect of PGE 2 on VSMC proliferation has been reported by several groups, the results are inconsistent, with both inhibitory and stimulatory effects reported. [17] [18] 47, 48 PGE 2 exerts its biological roles by 4 EP receptors, EP1 to EP4. Activation of EP receptors, with characteristic vascular distribution, evokes receptor-specific signaling pathways and results in distinct biological consequences. 20 Here, we showed the protective role of the EP2 receptor in restraining neointimal formation after vascular injury. Our study provides compelling evidence to support the EP2 receptor as a promising therapeutic target for treating restenosis after angioplasty.
EP2 is a G␣s-linked G protein-coupled receptor whose activation results in increased cAMP levels and subsequent activation of protein kinase A. 49 It is expressed in both endothelial cells and VSMCs. 47, 50 Although activation of EP2 in endothelial cells may increase monocyte adhesion and possibly initiate vascular inflammation in the early stage of atherosclerosis, 50 our study clearly demonstrates that EP2 is protective in restenosis development. First, EP2 expression was significantly upregulated in injured arteries and in PDGF-treated VSMCs. Second, EP2Ϫ/Ϫ mice exhibited increased VSMC proliferation and exacerbated neointimal formation. Third, activation or overexpression of EP2 resulted in inhibition of VSMC migration and proliferation. Fourth, activation and overexpression of EP2 in VSMCs led to G 0 /G 1 cell cycle arrest, inhibition of ERK phosphorylation, and reduction of cyclin D1 expression. Collectively, given the pivotal role that VSMCs play in initial thickening in atherosclerosis and restenosis, these findings point to a protective role of EP2 in pathological vascular remodeling after arterial injury. It should be pointed out that other EP receptors may also be involved in the pathogenesis of enhanced neointima formation, because the expression of EP1, EP3, and EP4 was differentially altered following vascular injury in EP2Ϫ/Ϫ mice.
As an endogenous ligand for EP2, PGE 2 is synthesized by 3 sequential enzymatic reactions that begin with a release of arachidonic acid from membrane phospholipids by phospholipase A2, conversion of arachidonic acid to the unstable endoperoxide intermediates PGG 2 and PGH 2 by COX-1 and -2, and finally isomerization of PGH 2 to PGE 2 by terminal PGE 2 synthase. 51 Among multiple enzymes involved in PGE 2 production, COX-1 and mPGES-1 are constitutively expressed in vascular tissues and cultured VSMCs. 16 In the present study, after arterial injury of mice, the expression of COX-2 but not COX-1 was transiently upregulated for less than 1 week. However, the mPGES-1 expression was constantly elevated for at least 4 weeks. Therefore, a sustained high level of mPGES-1 activity is essential for PGE 2 production and subsequent EP2 activation in injured vessels by coupling to both COX-1 and -2. 52 In the present study, we found cyclin D1 expression was significantly induced in neointimal VSMCs in EP2Ϫ/Ϫ mice, which suggests that EP2 may be an antiproliferative receptor. This observation was supported by both butaprost treatment and EP2 overexpression blocking PDGF-induced VSMC proliferation and cyclin D1 expression. In addition, the activation and overexpression of EP2 resulted in a significant suppression of PDGF-induced VSMC migration. Long-term activation of ERK is essential for cell cycle progression and migration, 34 -37,53 and the cAMP-PKA signaling pathway can arrest cells in the G 1 phase by suppressing phosphorylation of ERK. 38 The finding that butaprost significantly suppressed PDGF-induced phosphorylation of ERK1/2 suggests that cell cycle arrest, cyclin D1 reduction, and restraint migration are, at least in part, due to EP2-mediated inhibition of ERK signaling. In addition, the finding of the abolishment of the effect of EP2 overexpression on PDGF-induced ERK activation, cyclin D1 expression, and cell migration by the inhibition of PGE 2 synthesis further supports the role of the PGE 2 -EP2 signaling pathway in the regulation of VSMC proliferation and migration.
Conclusions
We demonstrated that the PGE 2 -EP2 signaling pathway plays a critical role in regulating the cellular response to acute vascular injury. Activation of EP2 inhibits the migration and proliferation of VSMCs by inducing cell cycle arrest. Deficiency of the EP2 receptor promotes VSMC proliferation and augments restenosis after angioplasty. These findings suggest that activation of EP2 may have potential implications in treating pathological vascular remodeling, such as restenosis after angioplasty. 
Supplement Material Supplementary methods：
Immunoprecipitation: Immunoprecipitation was performed as described previously 1 .
In brief, 250-500 µg total protein extracted from vascular smooth muscle cells was pre-cleared with 10 µl Protein G agarose beads in a final volume of 500 μl at 4°C for 1 hr, and the sample was then centrifuged at 13,000 rpm at 4°C for 1 min. After disposal of the pellet, 10 µl of primary antibody (200 µg/ml) was added into the supernatant, rotating on a Nutator for 2 hr at 4°C. After 2 hr, 40 µl CL-4B beads was added into each tube with rotating on a Nutator at 4°C overnight. The sample was centrifuged at 13,000 rpm for 1 min, and the resulting pellet beads were washed twice with 0. 
